While competition authorities have traditionally focused their attention in pharmaceutical mergers on unilateral effects, they are increasingly considering other theories of harm. Partner Maria Raptis, counsel Michael Frese and Julia Zhu and associate Marta Navarro Hernández discuss how authorities are now including broader innovation effects, conglomerate effects and coordinated effects in their assessment.
An extract from GCR’s The Guide to Life Sciences – Third Edition. The whole publication is available at https://globalcompetitionreview.com/guide/guide-life-sciences.